Novacyt (FR:ALNOV)
:ALNOV
Want to see FR:ALNOV full AI Analyst Report?
ALNOV Stock Chart & Stats
€0.40
<€0.01(0.56%)
At close: 4:00 PM EST
€0.40
<€0.01(0.56%)
Day’s Range― - ―
52-Week Range€0.29 - €1.04
Previous CloseN/A
Volume192.22K
Average Volume (3M)141.10K
Market Cap
€28.60M
Enterprise Value€16.88M
Total Cash (Recent Filing)€19.14M
Total Debt (Recent Filing)€10.44M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding72,588,090
10 Day Avg. Volume69,615
30 Day Avg. Volume141,103
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.03
Price to Sales (P/S)1.18
P/FCF Ratio-2.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€30.58M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA 63% blended gross margin, driven by high‑margin PCR/RUO products and Primerdesign (>80%), creates durable product-level profitability. This margin profile supports operating leverage and cash flow improvement as volumes scale, improving the pathway to sustainable EBITDA once OpEx normalises.
Clinical Franchise And Geographic GrowthA clinical-led mix (≈70% of revenue) with expanding NIPT and Asia‑Pacific exposure provides recurring, contractable revenue and geographic diversification. Durable clinical contracts and tender wins support repeat consumable sales and reduce reliance on one-off pandemic volumes over the medium term.
Regulatory Approvals (IVDR)IVDR accreditation strengthens market access and raises barriers to competitor substitution in Europe. Regulatory certification is a structural advantage that supports premium positioning for clinically focused assays and reduces long-term competitive risk, aiding stable revenue capture in regulated markets.
Bears Say
Liquidity And Cash BurnCash reserves have fallen materially with ~£11m consumed in FY25 and cash at £11m end‑Mar‑26 versus a monthly burn ~£825k. This creates a multi‑quarter financing sensitivity: failure to meet forecasted revenue or reduce burn would force dilutive financing or disrupt execution on strategic initiatives.
Structural Unprofitability And Negative Cash FlowSustained operating losses and multi-year negative operating/free cash flow indicate the core business has not yet scaled to cover fixed costs. Persistent cash consumption raises refinancing risk and means achieving durable profitability depends on sustained revenue growth and margin preservation over coming quarters.
Regulatory/product Setback (SMA)The SMA regulatory pause delays a planned product revenue stream and creates uncertainty on timing and margins. Reworking OEM arrangements or redesigning in‑house increases development cost and timetable risk, which can push out expected instrument/reagent pull‑through and slow revenue diversification.
Novacyt News
ALNOV FAQ
What was Novacyt’s price range in the past 12 months?
Novacyt lowest stock price was €0.29 and its highest was €1.04 in the past 12 months.
What is Novacyt’s market cap?
Novacyt’s market cap is €28.60M.
When is Novacyt’s upcoming earnings report date?
Novacyt’s upcoming earnings report date is Sep 24, 2026 which is in 96 days.
How were Novacyt’s earnings last quarter?
Novacyt released its earnings results on Apr 30, 2026. The company reported -€0.269 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.269.
Is Novacyt overvalued?
According to Wall Street analysts Novacyt’s price is currently Overvalued.
Does Novacyt pay dividends?
Novacyt does not currently pay dividends.
What is Novacyt’s EPS estimate?
Novacyt’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novacyt have?
Novacyt has 72,588,090 shares outstanding.
What happened to Novacyt’s price movement after its last earnings report?
Novacyt reported an EPS of -€0.269 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.514%.
Which hedge fund is a major shareholder of Novacyt?
Currently, no hedge funds are holding shares in FR:ALNOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novacyt
Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercialization. These vital diagnostic tools are employed in the detection of both cancer and a variety of infectious diseases. The company boasts an extensive international reach, serving markets throughout the United Kingdom, wider Europe, the United States, the Asia Pacific region, the Middle East, and Africa. Novacyt's operations are structured around three core segments. Primer Design specializes in the creation, production, and sale of molecular real-time qPCR testing devices and reagents, primarily for infectious disease diagnostics. Lab21 Products focuses on developing, manufacturing, and distributing a diverse portfolio of protein-based in-vitro diagnostic (IVD) products, also targeting infectious diseases. The IT-IS International segment is dedicated to engineering and fabricating PCR instruments used in the life sciences and food testing industries. The company's clientele principally includes hospitals and various corporate organizations.
ALNOV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented clear operational and strategic progress: revenue growth, product launches (LightBench Discover, DPYD), strong gross margin (63%), reduced OpEx and a narrowing of reported losses. Management completed an earnings-accretive acquisition (Southern Cross) and emphasized regulatory strength via IVDR approvals. Material headwinds remain — notably a large non-cash impairment (~GBP 14.4m), exceptional charges (~GBP 16m), reduced cash to GBP 11m at end-March 2026 and ongoing operating losses — but management articulated a clear plan to accelerate top-line growth and reduce cash burn. Highlights and lowlights are balanced: tangible improvements and growth catalysts exist, yet meaningful financial and execution risks persist in the near term.View all FR:ALNOV earnings summariesTechnical Analysis
MAUNA KEA TECHNOLOGIES
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―
Options Prices
Currently, No data available
---